Trial Profile
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Ibandronic acid
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Amgen
- 14 Nov 2012 Results reporting patient satisfaction presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.